Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan:39:e198-e206.
doi: 10.1200/EDBK_237829. Epub 2019 May 17.

New Treatment Options in Advanced Squamous Cell Lung Cancer

Paul K Paik  1   2 , Rathi Narayana Pillai  3 , Christopher S Lathan  4 , Sylvia A Velasco  4 , Vassiliki Papadimitrakopoulou  5
Affiliations
Free article
Review

New Treatment Options in Advanced Squamous Cell Lung Cancer

Paul K Paik et al. Am Soc Clin Oncol Educ Book. 2019 Jan.
Free article

Abstract

The past few years have witnessed a rapid shift in the treatments for patients with squamous cell lung cancers (SQCLCs) after the U.S. Food and Drug Administration approval of a number of immune checkpoint inhibitors as second-line therapies for patients with non-small cell lung cancers. These series of approvals marked the first substantial improvement in overall survival for patients with SQCLC in over a decade. Further gains have been made more recently with the incorporation of immune checkpoint inhibition in the first-line setting, either as monotherapy or in combination with chemotherapy. These advances have, however, exposed existing deficiencies in the management of this disease. Despite a deeper understanding of the genomic alterations that characterize SQCLCs and years of trial work targeting these alterations, personalized therapies remain out of hand. Future studies will continue to focus on identifying targeted approaches to expand the treatment options for our patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma.
    Wang Y, Song Y, Wang R, Wu Y, Li M, Xu K, He R, Wang Z, Li Q, Kong FS, Wang T. Wang Y, et al. Front Oncol. 2024 Apr 12;14:1265228. doi: 10.3389/fonc.2024.1265228. eCollection 2024. Front Oncol. 2024. PMID: 38680859 Free PMC article.
  • Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
    Niu Z, Jin R, Zhang Y, Li H. Niu Z, et al. Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-01200-x. Signal Transduct Target Ther. 2022. PMID: 36198685 Free PMC article. Review.
  • CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer.
    Sauta E, Reggiani F, Torricelli F, Zanetti E, Tagliavini E, Santandrea G, Gobbi G, Strocchi S, Paci M, Damia G, Bellazzi R, Ambrosetti D, Ciarrocchi A, Sancisi V. Sauta E, et al. Cancers (Basel). 2021 Jul 12;13(14):3477. doi: 10.3390/cancers13143477. Cancers (Basel). 2021. PMID: 34298691 Free PMC article.
  • A proteogenomic portrait of lung squamous cell carcinoma.
    Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA; Clinical Proteomic Tumor Analysis Consortium. Satpathy S, et al. Cell. 2021 Aug 5;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016. Cell. 2021. PMID: 34358469 Free PMC article.
  • [Inhibition of Lung Squamous Cancer Target HMGCS1 Promotes Cellular Ferroptosis].
    Ni Y, Yang Y, Zhang L. Ni Y, et al. Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):330-336. doi: 10.3779/j.issn.1009-3419.2024.101.12. Zhongguo Fei Ai Za Zhi. 2024. PMID: 38880920 Free PMC article. Chinese.
See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources